PBMs profit off expensive niche meds

Pharmacy benefits managers are building lucrative side businesses in specialty drugs, becoming in some cases the sole distributors for certain niche medications. Critics say distributing these drugs--whose prices are rising much faster than other meds'--could conflict with the PBMs' primary mission of keeping overall drug prices down for health insurers.

- read the story in the New York Times

Suggested Articles

CEPI, which started to help prepare the world for new outbreaks, has awarded Inovio and Moderna money for vaccine work against the new coronavirus.

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.